低剂量阿司匹林:全髋关节置换术后静脉血栓栓塞预防在所有风险分层中最安全的预防方法
该回顾性队列研究基于大型国家数据库分析2012至2023年147437例初次全髋关节置换术患者,按2022年国际共识会议标准分为静脉血栓栓塞高风险和低风险组,比较低剂量阿司匹林(81 mg)与其他抗凝药的90天结局。在两组中阿司匹林单药预防均与更低的深静脉血栓、肺栓塞、出血、消化道出血和死亡率相关,支持国际共识会议将阿司匹林作为安全有效的广泛适用血栓预防策略的推荐。
要点
- 低剂量阿司匹林使用率从2012年的0.4%上升至2023年的60.9%。
- 在高风险和低风险组中,阿司匹林单药预防均与更低的血栓栓塞、出血和死亡率相关。
- 研究结果支持2022年国际共识会议将阿司匹林作为全髋关节置换术后血栓预防优选方案的推荐。
核心结论
- 低剂量阿司匹林在高风险和低风险全髋关节置换术患者中均与显著更低的血栓栓塞、出血和死亡率结局相关。
- 这些发现支持国际共识会议将阿司匹林作为全髋关节置换术后安全、有效且广泛适用的血栓预防策略的推荐。
研究设计与样本
- 回顾性队列研究,分析2012年至2023年接受初次全髋关节置换术的患者,使用大型国家数据库。
- 共纳入147437例全髋关节置换术患者,根据国际共识会议标准和既往国家分析中识别的合并症分为静脉血栓栓塞高风险组和低风险组。
- 化学预防方案包括低剂量阿司匹林(81 mg)和其他抗凝药,接受高剂量阿司匹林的患者被排除。
- 采用倾向性评分匹配(1:1)控制人口学和临床变量。
- 统计显著性定义为P < 0.05。
主要发现
- 在高风险组中,阿司匹林单药预防与其他药物相比,深静脉血栓的比值比为0.29。
- 在低风险组中,阿司匹林单药预防与其他药物相比,深静脉血栓的比值比为0.16。
- 在高风险和低风险组中,阿司匹林单药预防与其他药物相比,肺栓塞的比值比为0.32至0.25。
- 在高风险和低风险组中,阿司匹林单药预防与其他药物相比,出血的比值比为0.13至0.09。
- 在高风险和低风险组中,阿司匹林单药预防与其他药物相比,消化道出血的比值比为0.42至0.27,死亡率的比值比为0.33至0.48。
关键数值与推荐
- 2022年国际共识会议(ICM)推荐低剂量阿司匹林作为所有全髋关节置换术患者的首选化学预防方案。
- 低剂量阿司匹林使用率从2012年的0.4%上升至2023年的60.9%。
- 结局包括90天深静脉血栓、肺栓塞、出血、血肿、消化道出血、感染、心肌梗死、卒中、死亡率、翻修、急诊就诊和再入院率。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Venous thromboembolism (VTE) remains a major concern following total hip arthroplasty (THA). While multiple agents are used for chemoprophylaxis, the 2022 International Consensus Meeting (ICM) on VTE endorsed low-dose aspirin as the preferred option for all THA patients. However, data comparing aspirin with other anticoagulants across different VTE risk profiles remain limited. METHODS: This retrospective cohort study analyzed patients undergoing primary THA between 2012 and 2023 using a large national database. Patients were stratified into VTE high-risk and low-risk groups based on ICM criteria and comorbidities identified in prior national analyses. Chemoprophylactic regimens included low-dose aspirin (81 mg) and other anticoagulants; patients receiving high-dose aspirin were excluded. Among 147,437 THA patients, use of low-dose aspirin increased from 0.4% in 2012 to 60.9% in 2023. Outcomes included 90-day rates of deep vein thrombosis, pulmonary embolism, hemorrhage, hematoma, gastrointestinal bleeding, infection, myocardial infarction, stroke, mortality, revision, emergency department visits, and readmissions. Propensity score matching (1:1) was applied to control for demographic and clinical variables. Statistical significance was defined as P < 0.05. RESULTS: In both high- and low-risk groups, aspirin-only prophylaxis was associated with lower odds of deep vein thrombosis (odds ratio (OR): 0.29 high-risk, 0.16 low-risk), pulmonary embolism (OR: 0.32 to 0.25), hemorrhage (OR: 0.13 to 0.09), gastrointestinal bleeding (OR: 0.42 to 0.27), and mortality (OR: 0.33 to 0.48) compared to alternative agents. CONCLUSIONS: Low-dose aspirin was associated with significantly lower rates of thromboembolic, bleeding, and mortality outcomes in both high- and low-risk THA patients. These findings support the ICM recommendation of aspirin as a safe, effective, and broadly applicable thromboprophylaxis strategy following THA. LEVEL OF EVIDENCE: Therapeutic Level III.
引用
- Porto JR, Lavu MS, Hecht CJ, et al. Low-Dose Aspirin: The Safest Prophylactic Approach for Venous Thromboembolism Prevention Following Total Hip Arthroplasty Across All Risk Profiles. J Arthroplasty. 2025. PMID: 40992597. doi:10.1016/j.arth.2025.09.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。